Therefore, we postulate that targeting CBF-β could enhance tumour regression in response to immune checkpoint inhibition, as has been observed in trials upregulating type I IFN responses through synthetic cyclic dinucleotides and STING agonists90,91. The gene discussed is CBFB; the disease is neoplasm.